Telehealth fights for GLP-1

Ro and Amazon are turning obesity telehealth into a pricing and care-management fight, not just a prescription race. (ro.co) Ro now lists its Body membership at $39 for the first month, $149 a month on the standard plan, and as low as $74 a month with annual prepayment. The company says medication is billed separately and the membership includes provider visits, coaching, lab work, and insurance support. (ro.co) Amazon One Medical said on April 21 that it launched a nationwide GLP-1 management program through primary care clinicians, with personalized treatment plans, nutrition and exercise support, and care coordination through Amazon Pharmacy. Its public program page says clinicians decide whether drugs such as Wegovy or Zepbound are appropriate and send prescriptions to a patient’s preferred pharmacy. (usatoday.com and health.amazon.com) GLP-1 drugs mimic a hormone involved in blood sugar and appetite control, which is why they became blockbuster obesity treatments before telehealth platforms built subscription businesses around them. One Medical’s explainer says medicines such as Wegovy and Zepbound were first developed for type 2 diabetes and later became widely used for weight loss. (onemedical.com) The economics changed after the U.S. Food and Drug Administration said on February 21, 2025, that the semaglutide injection shortage was resolved, narrowing the opening that had allowed widespread compounding during shortages. In February 2026, the agency also said it intended to restrict active ingredients used in non-FDA-approved compounded GLP-1 drugs. (fda.gov and fda.gov) That pushed telehealth companies toward branded supply, insurance navigation, and monthly program design. Hims & Hers said in March that it had added Novo Nordisk’s FDA-approved GLP-1 medicines, including the Wegovy pill, while continuing to market weight-loss care as an ongoing service. (investors.hims.com and hims.com) Investors treated Ro’s new pricing as a competitive shot at Hims. Stocktwits reported Hims shares were down about 3% in premarket trading on Thursday after Ro’s cuts, citing Hims pricing of about $39 initially and $149 a month after that. (stocktwits.com) Drugmakers are also resetting the price umbrella over this market. Novo Nordisk said in February it would cut the U.S. list price of Wegovy, Ozempic, and Rybelsus to $675 a month effective January 1, 2027, while saying the change would not alter separate direct-to-patient self-pay prices. (prnewswire.com) Ro is also broadening its formulary as price pressure rises. On April 9, Ro said it added Eli Lilly’s oral GLP-1 drug Foundayo, with cash-pay pricing starting at $149 a month for the lowest dose before membership fees. (ro.co) The result is a market where the prescription is only one line item. The harder sell is keeping patients enrolled, covered, and adherent long enough for expensive weight-loss drugs to become a durable business. (fiercehealthcare.com and ro.co)